Caribou Biosciences宣布FDA授予其同种异体抗BCMA CAR-T细胞疗法CB-011再生医学先进疗法资格

美股速递
Mar 31

生物技术公司Caribou Biosciences宣布,其研发的同种异体抗BCMA嵌合抗原受体T细胞疗法CB-011,已获得美国食品药品监督管理局授予的再生医学先进疗法资格。这一认定是针对该疗法在特定适应症中的潜力所给予的官方认可。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10